Together, our in vitro and in vivo data suggest the abrogation of BTK expression or its activity in patients with HNSCC as a powerful treatment option to suppress tumor growth as well as tumor induced angiogenesis. The gene discussed is BTK; the disease is head and neck squamous cell carcinoma.